PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
|
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
  • [31] A comparison of cost effectiveness of peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Crtaxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 174 - 175
  • [32] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [33] Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.
    Jensen, CDM
    Bernstein, DE
    Hassanein, TI
    Foster, GR
    Lee, SS
    Cheinquer, H
    Craxi, A
    Cooksley, WGE
    Klaskala, W
    Green, J
    HEPATOLOGY, 2002, 36 (04) : 603A - 603A
  • [34] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [35] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [36] An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC)
    Hornberger, J
    Dusheiko, G
    Lewis, G
    Patel, K
    HEPATOLOGY, 2005, 42 (04) : 653A - 653A
  • [37] Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus)
    Balan, V
    Zeuzem, S
    Sette, H
    Fried, M
    Jensen, D
    Pastore, G
    Marcellin, P
    Sedarati, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 19 - 19
  • [38] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [39] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [40] PEG-IFN alfa-2a plus ribavirin is superior compared to high dose consensus interferon (CIFN) and ribavirin in the treatment of patients with chronic hepatitis C
    Witthoeft, T.
    Fuchs, M.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S248 - S248
12345